Salarius Pharmaceuticals Inc (SLRX) Stock
SLRX is no longer traded. Salarius Pharmaceuticals was delisted from the Nasdaq in January 2026.
Prices on this page are historical; the last trade was January 9, 2026 at $0.82.
Salarius Pharmaceuticals stock price history
SLRX final trading statistics
- Final close
- $0.82
- Final trading day
- Jan 9, 2026
- Market cap at delisting
- $4.81M
- Shares outstanding
- 5.86M
- Final 52-week range
- $0.43 – $7.20
- Avg. volume (final 3 mo.)
- 1,944,408
- All-time high (split-adj.)
- $1000000.00 · Jan 2015
- All-time low (split-adj.)
- $0.54 · Jan 2026
- Return since IPO
- -100.0%
- Beta
- 0.32
- Book value / share
- $4.50
- Price / book
- 0.18
Salarius Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | -$5.6M | -$15.19 |
| FY2023 | $0.00 | -$12.5M | -$4.53 |
| FY2022 | $0.00 | -$31.6M | -$10.80 |
| FY2021 | $1.84M | -$12.8M | -$7.50 |
| FY2020 | $5.23M | -$7.4M | -$13.75 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
Salarius Pharmaceuticals stock FAQ
What happened to Salarius Pharmaceuticals stock?
Salarius Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $0.82 on January 9, 2026.
Is SLRX stock still trading?
No. SLRX was delisted from the Nasdaq in January 2026 and no longer trades on a U.S. exchange.
What was the last price of SLRX stock?
SLRX closed at $0.82 on its final trading day, January 9, 2026, for a market value of about $4.81M.
What were Salarius Pharmaceuticals's revenue and earnings in its last full fiscal year?
Salarius Pharmaceuticals reported revenue of $0.00 and net income of -$5.6M in fiscal 2024, its last full year as a public company.
When did Salarius Pharmaceuticals go public?
Salarius Pharmaceuticals Inc stock began trading on January 29, 2015.